Evidence map›Paper›PMID 40625098›Full record

ArticleTransplant infectious disease : an official journal of the Transplantation Society

Prognostic Impact of Cytomegalovirus Reactivation After Transplantation From Cord Blood Compared to Other Donor Sources in Patients With Adult T-Cell Leukemia/Lymphoma in the Pre-Letermovir Era.

Takuya Fukushima, Hidehiro Itonaga, Hikaru Sakamoto, Wataru Takeda, Masahito Tokunaga, Takeharu Kato, Takuro Kuriyama, Toshiro Kawakita, Machiko Fujioka, Yasuhiko Miyazaki and 13 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Transplant infectious disease : an official journal of the Transplantation Society. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors.

Takuya FukushimaLaboratory of Hematoimmunology, Department of Clinical Laboratory Sciences, School of Health Sciences, Faculty of Medicine, University of the Ryukyus, Okinawa, Japan.
Hidehiro ItonagaTransfusion and Cell Therapy Unit, Nagasaki University Hospital, Nagasaki, Japan.ORCID https://orcid.org/0000-0003-1438-3623
Hikaru SakamotoDepartment of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Wataru TakedaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Masahito TokunagaDepartment of Hematology, Imamura General Hospital, Kagoshima, Japan.
Takeharu KatoDepartment of Hematology, Nagasaki University Hospital, Nagasaki, Japan.
Takuro KuriyamaDepartment of Hematology, Hamanomachi Hospital, Fukuoka, Japan.
Toshiro KawakitaDepartment of Hematology, NHO Kumamoto Medical Center, Kumamoto, Japan.
Machiko FujiokaDepartment of Hematology, Sasebo City General Hospital, Sasebo, Japan.
Yasuhiko MiyazakiDepartment of Hematology, Oita Prefectural Hospital, Oita, Japan.
Naoyuki UchidaDepartment of Hematology, Federation of National Public Service Personnel Mutual Aid Associations Toranomon Hospital, Tokyo, Japan.
Yasuo MoriHematology, Oncology & Cardiovascular Medicine, Kyushu University Hospital, Fukuoka, Japan.ORCID https://orcid.org/0000-0001-6425-1720
Hirohisa NakamaeDepartment of Hematology, Osaka Metropolitan University Hospital, Osaka, Japan.ORCID https://orcid.org/0000-0003-4203-990X
Masao OgataDepartment of Hematology, Oita University Hospital, Yufu, Japan.ORCID https://orcid.org/0000-0002-4896-5878
Kazunori ImadaDepartment of Hematology, Japanese Red Cross Osaka Hospital, Osaka, Japan.
Makoto OnizukaDepartment of Hematology/Oncology, Tokai University School of Medicine, Isehara, Japan.
Kazuho MorichikaSecond Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, University of the Ryukyus Hospital, Okinawa, Japan.
Yoshinobu KandaDivision of Hematology, Jichi Medical University, Shimotsuke, Japan.ORCID https://orcid.org/0000-0002-4866-9307
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Yoshiko AtsutaJapanese Data Center for Hematopoietic Cell Transplantation, Nagakute, Japan.
Shigeo FujiDepartment of Hematology, Osaka International Cancer Center Institute, Osaka, Japan.ORCID https://orcid.org/0000-0001-5118-7950
Makoto YoshimitsuDepartment of Hematology and Rheumatology, Kagoshima University Hospital, Kagoshima, Japan.
ATL Working Group of the Japanese Society for Transplantation and Cellular Therapy

Funding

Grant-in-Aid for Scientific Research (KAKENHI)Japan Society for the Promotion of Science 22K08480Nagasaki-ken Medical AssociationTakeda Science Foundation
6 · The paper itself

Abstract

backgroundCytomegalovirus reactivation (CMV-react) is an indicator for the worse non-relapse mortality (NRM) and overall survival (OS) after allogeneic hematopoietic stem cell transplantation using HLA-matched related donor (MRD) and unrelated donor (URD) for adult T-cell leukemia/lymphoma (ATL). However, it remains unclear whether CMV-react correlates with outcomes after unrelated cord blood (U-CB) transplantation.

methodsWe conducted a retrospective nationwide study to evaluate the impact of CMV-react on the outcomes after posttransplant 100 days. Data were collected from 205, 461, and 268 patients who used MRD, URD, and U-CB, respectively, between 2001 and 2022 and survived without relapse for over 100 days after transplantation.

resultsIn multivariate analyses, CMV-react correlated with worse OS in the MRD (hazard ratio [HR], 1.56; 95% confidence interval [CI], 1.02-2.39; p = 0.04) and URD groups (HR, 1.45; 95% CI, 1.00-2.09; p = 0.05), but not in the U-CB group (HR, 1.34; 95% CI, 0.88-2.03; p = 0.2). CMV-react correlated with higher NRM in the MRD (HR, 1.79; 95% CI, 1.01-3.16; p = 0.05) and URD groups (HR, 1.68; 95% CI, 1.01-2.82; p = 0.05), but not in the U-CB group (HR, 1.16; 95% CI, 0.62-2.19; p = 0.6). CMV-react did not correlate with the incidence of relapse in any group.

conclusionCMV-react was not associated with the outcomes in the U-CB group, while CMV-react correlates with worse OS and NRM in the MRD and URD groups, indicating the need for a more intensive strategy for late-phase complications in U-CB transplantation for ATL with and without CMV-react.

Indexed as

Cord Blood Stem Cell TransplantationCytomegalovirusCytomegalovirus InfectionsHematopoietic Stem Cell TransplantationLeukemia-Lymphoma, Adult T-CellVirus ActivationAcetatesAdultAgedAntiviral AgentsFemaleHumansMaleMiddle AgedPrognosisQuinazolinesAcetatesAntiviral AgentsletermovirQuinazolinesadult T‐cell leukemia/lymphomaallogeneic hematopoietic stem cell transplantationcytomegalovirus

Identifiers

PMID40625098
PMCPMC12519938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.